Merrill keeps ZymoGenetics at buy

ZymoGenetics, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy ahead of the company's third-quarter results. The analyst estimates for the quarter include total revenues of $9.3 million, research and development expenses of $39.0 million and a net loss of $0.56 per share. Sambasivam will look for an update on the planned rhThrombin Biologics License Application filing by year-end, commentary on the competitive landscape including recent data from Omrix and an update on commercialization strategy during the earnings call. Shares of the Seattle-based pharmaceutical company were down 31 cents, or 1.87%, at $16.31. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.